EJC Supplements

Published by: Pergamon-Elsevier Science Ltd  

People

  1. Solit
    Solit
  2. Rosen
    Rosen
  3. Scher
    Scher
  4. Chandarlapaty
    Chandarlapaty
  5. Fagin
    Fagin
  6. Fleisher
    Fleisher
  7. Mellinghoff
    Mellinghoff
  8. Morris
    Morris
  9. Pfister
    Pfister
  10. Sawyers
    Sawyers

Groups

  1. GSK Faculty (9)
  2. Human Oncology and Pathogenesis Program (9)
  3. Department of Medicine (8)
  4. Solid Tumor Oncology Division (8)
  5. Genitourinary Oncology Service (7)
  6. Molecular Pharmacology and Chemistry Program Faculty (6)
  7. Sloan Kettering Institute Faculty (6)
  8. Breast Medicine Service (5)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  10. Hematologic Malignancies, Division of (2)
Search Within
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (9)
Groups
  1. GSK Faculty (9)
  2. Human Oncology and Pathogenesis Program (9)
  3. Department of Medicine (8)
  4. Solid Tumor Oncology Division (8)
  5. Genitourinary Oncology Service (7)
  6. Molecular Pharmacology and Chemistry Program Faculty (6)

More Groups

People
  1. David Solit (6)
  2. Neal Rosen (5)
  3. Qing Ye (3)
  4. Howard Scher (2)
  5. Agnes Viale (1)
  6. Ayana Sawai (1)

More People

Years
  1. 2008 (2)
  2. 2007 (2)
  3. 2006 (4)
  4. 2005 (1)
Publishers
  1. Pergamon-Elsevier Science Ltd (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Meeting Abstract

    Scher, H.; Beer, T.; Higano, C.; Logothetis, C.; Shelkey, J.; Hung, D.; Hirmand, M.; Larson, S.; Fleisher, M.; Sawyers, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • RET inhibition: Therapeutic implications in thyroid cancer
    Meeting Abstract

    Mitsiades, N.; Fagin, J. A.; Pfister, D. G.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Targeting MEK in tumors with BRAF and RAS mutations
    Meeting Abstract

    Solit, D.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Biomarkers of brain tumors to EGFR-TKI
    Meeting Abstract

    Mellinghoff, I.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Combined inhibition of PI3K/AKT and MAPK signaling is required to inhibit translational initiation and to induce apoptosis in human tumors
    Meeting Abstract

    She, Q. B.; Ye, Q.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 function downregulates EGFR and sensitizes EGFR-mutant xenografts to paclitaxel
    Meeting Abstract

    Sawai, A.; Greulich, H.; Ye, Q.; Sellers, W.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • A phase I/II trial to assess tolerability and efficacy of RAD-001 with gefitinib in patients with glioblastoma multiforme and castrate metastatic prostate cancer
    Meeting Abstract

    Shaffer, D. R.; Abrey, L.; Beekman, K.; Morris, M.; Eicher, C.; Kelly, W. K.; Slovin, S.; Solit, D.; Rosen, N.; Scher, H. I.
    EJC Supplements (2005)

    Fulltext@MSK | Save

    • EJC Supplements – authorized name for:

    Name ISSN / ISBN Publisher
    EJC Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    EJC Supplements 1359-6349 Unknown
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    European Journal of Cancer, Supplement 13596349 Elsevier Inc.
    European Journal of Cancer, Supplement 13596349 Unknown